Medpace Holdings (MEX:MEDP) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MEDP Medpace Holdings Inc MEX:MEDP
95 GF Score
Price MXN7,022.03
GF Value MXN6,131.53
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Medpace Holdings is: No Data: Cannot be evaluated.

Medpace Holdings  (MEX:MEDP) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Medpace Holdings Risk Assessment Related Terms

MEX:MEDP vs ICLR, RVTY, CRL: Risk Assessment Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medpace Holdings Risk Assessment vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Risk Assessment falls into.


MEX:MEDP
95GF Score
Medpace Holdings Inc MEX:MEDP
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.

Key valuation signals for MEX:MEDP:

  • Risk Assessment:
  • GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medpace Holdings Business Description

Other Exchanges MEDP:USA01P:Germany
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score

Get the complete analysis for MEX:MEDP

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN7,022.03
Price
MXN6,131.53
GF Value